Residency · Residency · Geriatrics

Hypertension in the Elderly - Targets and Treatment

Introduction

Hypertension is the most prevalent modifiable cardiovascular risk factor in older adults, affecting 70 to 80 percent of adults aged 65 and older. Isolated systolic hypertension (ISH), characterized by elevated systolic blood pressure with normal or low diastolic blood pressure, predominates after age 60 and reflects the arterial stiffening that characterizes vascular aging. Wide pulse pressure, defined as systolic minus diastolic blood pressure exceeding 60 mmHg, is an independent cardiovascular risk factor in elderly populations. Hypertension is the leading modifiable risk factor for stroke, heart failure, chronic kidney disease, cognitive decline, and cardiovascular death. Treatment of hypertension in the elderly yields substantial benefits, reducing stroke by 30 to 40 percent, heart failure by 50 percent, and cardiovascular mortality by 20 to 30 percent.

Pathophysiology in the Elderly

The pathophysiology of hypertension in the elderly is driven primarily by arterial stiffening resulting from elastin fragmentation, collagen deposition, and medial calcification (Monckeberg sclerosis). Increased pulse wave velocity causes early reflected waves that augment systolic pressure, resulting in the widened pulse pressure characteristic of geriatric hypertension. Reduced baroreceptor sensitivity impairs blood pressure regulation, creating the paradoxical coexistence of orthostatic hypotension and postprandial hypotension alongside supine hypertension. Salt sensitivity increases with age, making volume-dependent hypertension more common. Reduced renal sodium excretion capacity further contributes to volume expansion.

Pseudohypertension deserves consideration: incompressible, calcified brachial arteries can produce falsely elevated cuff readings. This entity should be suspected when high cuff readings are recorded without corresponding end-organ damage. The Osler maneuver, in which the radial artery remains palpable when the cuff is inflated above systolic pressure, has historically been used to detect pseudohypertension but has poor sensitivity.

BP Measurement Considerations

Proper measurement technique is essential and particularly important in elderly patients. The patient should rest for 5 minutes before measurement, the arm should be supported at heart level, an appropriate cuff size must be used, and the patient should not talk during measurement. Orthostatic blood pressure should always be checked in elderly patients, measuring blood pressure supine and then at 1 and 3 minutes after standing, as orthostatic hypotension is present in 20 to 30 percent of hypertensive elderly adults.

White coat hypertension, with a prevalence of 15 to 30 percent in elderly patients, should be confirmed with ambulatory blood pressure monitoring (ABPM) or home blood pressure monitoring (HBPM). ABPM diagnostic thresholds include a 24-hour average of 130/80 mmHg or above, daytime average of 135/85 or above, and nighttime average of 120/70 or above. HBPM criteria require an average of 135/85 or above on at least 12 readings over 3 to 7 days. Masked hypertension, defined as normal office blood pressure but elevated out-of-office readings, is common in elderly patients and associated with increased cardiovascular risk. An interarm blood pressure difference exceeding 10 mmHg suggests subclavian stenosis, and the higher arm should be used for management decisions.

Treatment Targets — The Evidence

Landmark Trials in Elderly Hypertension

The evidence base for treating hypertension in the elderly rests on several landmark trials. The SHEP trial (1991) demonstrated that chlorthalidone-based treatment in patients with isolated systolic hypertension aged 60 and older, targeting systolic blood pressure below 160 mmHg, reduced stroke by 36 percent and heart failure by 54 percent. The Syst-Eur trial (1997) showed that nitrendipine-based treatment in ISH patients aged 60 and older reduced stroke by 42 percent and, in a substudy, reduced dementia by 50 percent.

The HYVET trial (2008) was a landmark achievement, being the first trial to demonstrate treatment benefit in the very elderly (age 80 and older). Using indapamide with or without perindopril to target systolic blood pressure below 150 mmHg, the trial showed reductions in stroke (30 percent), heart failure (64 percent), and all-cause mortality (21 percent). However, the trial excluded frail, institutionalized, and cognitively impaired patients, limiting generalizability to the broader elderly population.

The SPRINT trial (2015) compared intensive treatment (systolic blood pressure below 120 mmHg) versus standard treatment (systolic below 140 mmHg) in patients aged 50 and older with elevated cardiovascular risk. The primary outcome showed a 25 percent reduction in major cardiovascular events with intensive treatment. The subgroup of patients aged 75 and older (n=2,636) showed consistent benefit with a 34 percent reduction in the primary outcome and a number needed to treat of 28 over 3.2 years. Critically, SPRINT used automated office blood pressure (AOBP) measurements, which read approximately 5 to 10 mmHg lower than routine office measurement, meaning that a SPRINT target of below 120 corresponds to approximately below 130 with conventional measurement. Intensive treatment carried increased risks of hypotension (2.4 percent versus 1.4 percent), syncope (2.3 percent versus 1.7 percent), acute kidney injury (4.4 percent versus 2.6 percent), and electrolyte abnormalities. The trial excluded patients with diabetes, prior stroke, institutionalization, advanced dementia, and standing systolic blood pressure below 110 mmHg. The STEP trial (2021) studied Chinese elderly patients aged 60 to 80 and demonstrated a 26 percent reduction in cardiovascular events with intensive (systolic 110 to 130) versus standard (130 to 150) treatment.

Current Guideline Targets

The AHA/ACC 2017 guidelines recommend a target below 130/80 mmHg for all adults, applying to elderly patients with an emphasis on shared decision-making. The ESC/ESH 2023 guidelines recommend a target systolic of 120 to 129 mmHg if tolerated in patients aged 65 and older, and 130 to 139 mmHg in those aged 80 and older or those who are frail. The AGS 2023 recommendation is for systolic below 130 mmHg in community-dwelling adults aged 65 and older with reasonable functional status, with individualization for frail elderly, advanced dementia, and limited life expectancy.

A practical approach synthesizes these guidelines: target systolic 130 to 139 mmHg in most elderly patients; below 130 in robust elderly with high cardiovascular risk; 140 to 150 in frail patients, those with advanced dementia, or limited life expectancy; and avoid systolic below 110 and diastolic below 60 in all elderly patients.

<image>A comparison chart of BP treatment targets across major guidelines and clinical trials for elderly patients. Create a horizontal timeline showing landmark trials (SHEP 1991, Syst-Eur 1997, HYVET 2008, SPRINT 2015, STEP 2021) with their populations, targets, and key results along the top. Below, show a comparison table of current guideline recommendations from AHA/ACC 2017, ESC/ESH 2023, and AGS. At the bottom, create a patient-stratified target diagram showing recommended targets based on patient characteristics: Robust elderly (SBP <130), Community-dwelling with comorbidities (SBP 130-139), Frail elderly (SBP <150, avoid <120), Advanced dementia/end-of-life (SBP <150, focus on symptom management, consider deprescribing). Include a caution box noting that SPRINT used AOBP measurements which read 5-10 mmHg lower than conventional office readings, meaning a SPRINT target of <120 corresponds to approximately <130 with conventional measurement.</image>

Pharmacological Treatment

First-Line Agents

Thiazide and thiazide-like diuretics have the most extensive evidence base in elderly hypertension. Chlorthalidone at 12.5 to 25 mg or indapamide at 1.25 to 2.5 mg are the preferred agents. Chlorthalidone is preferred over hydrochlorothiazide due to its longer half-life (45 to 60 hours versus 6 to 12 hours), more potent blood pressure reduction, and robust outcomes data from the SHEP, HYVET, and ALLHAT trials. Adverse effects include hypokalemia, hyponatremia (with the highest risk in thin elderly women, where it can be severe), hyperuricemia, glucose intolerance, and orthostatic hypotension. Electrolytes should be monitored within 2 to 4 weeks of initiation.

ACE inhibitors and ARBs, such as lisinopril 5 to 40 mg and losartan 25 to 100 mg, are preferred when diabetes with proteinuria, chronic kidney disease, heart failure, or post-myocardial infarction are present. Adverse effects include hyperkalemia, acute kidney injury (particularly with concurrent NSAIDs or dehydration), cough (ACE inhibitors), and angioedema (more common with ACE inhibitors than ARBs). ACE inhibitors and ARBs should not be combined, as the ONTARGET trial demonstrated increased adverse events without benefit.

Dihydropyridine calcium channel blockers, particularly amlodipine at 2.5 to 10 mg and nifedipine XL at 30 to 90 mg, are well-tolerated in elderly patients and effective for isolated systolic hypertension. Peripheral edema is the most common adverse effect, occurring in a dose-dependent fashion in 10 to 30 percent at amlodipine 10 mg. This edema often responds to the addition of an ACE inhibitor or ARB, as the venodilation from RAAS inhibition offsets the arteriolar dilation from the calcium channel blocker.

Second-Line and Add-On Agents

Beta-blockers are not first-line agents for uncomplicated hypertension in the elderly, as they provide inferior stroke prevention compared to other agents (LIFE trial). They are indicated when heart failure with reduced ejection fraction, post-myocardial infarction, rate control for atrial fibrillation, or angina is present. Cardioselective agents (metoprolol succinate, bisoprolol) are preferred, and atenolol should be avoided in elderly patients based on evidence of inferiority. Aldosterone antagonists, specifically spironolactone at 12.5 to 25 mg, are the most effective add-on for resistant hypertension, as demonstrated in the PATHWAY-2 trial where spironolactone was superior to bisoprolol and doxazosin as a fourth agent. Alpha-blockers such as doxazosin should be avoided as first-line therapy based on the ALLHAT trial showing increased heart failure compared to chlorthalidone, though they may be used for concurrent benign prostatic hyperplasia with hypertension. Centrally acting agents including clonidine and methyldopa should be avoided in elderly patients due to sedation, rebound hypertension, and falls risk.

Combination Therapy

Most elderly patients require two or more medications to reach blood pressure targets. Preferred combinations include ACE inhibitor/ARB plus calcium channel blocker (supported by the ACCOMPLISH trial) or ACE inhibitor/ARB plus thiazide. Single-pill combinations such as amlodipine/benazepril, amlodipine/valsartan, and losartan/hydrochlorothiazide improve adherence. Combinations to avoid include ACE inhibitor plus ARB, and beta-blocker plus non-dihydropyridine calcium channel blocker (heart block risk).

Orthostatic Hypotension — The Geriatric Paradox

The coexistence of supine or seated hypertension with orthostatic hypotension is common in 20 to 30 percent of elderly patients, creating a significant treatment challenge: lowering blood pressure improves long-term cardiovascular risk but may worsen orthostatic symptoms and fall risk. Management requires measuring standing blood pressure at every visit. When symptomatic orthostatic hypotension is present, offending medications should be reduced or eliminated, particularly alpha-blockers and diuretics (which may be moved to evening dosing). Antihypertensive medications should generally not be taken at bedtime if nocturnal diuresis or nocturia causes nighttime falls, unless nocturnal hypertension is the primary concern. Non-pharmacological measures including compression stockings, adequate hydration, rising slowly, and ankle pump exercises before standing are essential. When severe orthostatic hypotension causes symptomatic falls, accepting higher blood pressure targets and prioritizing safety is appropriate.

Special Populations

Hypertension in Advanced Dementia

Deprescribing antihypertensive medications may be appropriate when goals of care are comfort-focused, when systolic blood pressure is consistently below 120 mmHg with symptoms (dizziness, falls), or when evidence of treatment-related harm (falls, syncope, acute kidney injury) exists. The PARTAGE study provided important evidence: systolic blood pressure below 130 mmHg on two or more antihypertensive medications in nursing home residents with dementia was associated with increased cognitive decline and mortality. Aggressive blood pressure targets should not be pursued in advanced dementia, with liberalization to systolic blood pressure of 140 to 160 mmHg when goals are comfort-focused.

Hypertension in Acute Stroke

In ischemic stroke, blood pressure should not be lowered unless it exceeds 220/120 mmHg, or 185/110 mmHg if thrombolysis is planned. In hemorrhagic stroke, the INTERACT2 trial demonstrated that targeting systolic blood pressure below 140 mmHg within 6 hours is safe and may improve outcomes.

Resistant Hypertension

Resistant hypertension is defined as blood pressure remaining above goal despite three medications at optimal doses, including a diuretic. The evaluation should rule out non-adherence (the most common cause), white coat effect, and secondary causes including renal artery stenosis, primary aldosteronism, sleep apnea, and chronic kidney disease. Spironolactone at 25 mg is the most effective add-on for resistant hypertension regardless of age, as demonstrated in the PATHWAY-2 trial.

<image>A practical medication selection algorithm for elderly hypertension. Start with "Confirmed hypertension in elderly patient (office, ABPM, or HBPM)." Show assessment of orthostatic BP (mandatory in elderly). First decision: compelling indications present? If HFrEF → ACE-I/ARB + beta-blocker; if CKD with proteinuria → ACE-I/ARB; if post-MI → beta-blocker + ACE-I/ARB; if diabetes → ACE-I/ARB. If no compelling indication → start with thiazide-like (chlorthalidone) OR CCB (amlodipine) OR ACE-I/ARB. If not at target after 4 weeks → add second agent from different class. If not at target on 3 agents → check adherence, exclude white coat, check for secondary causes → add spironolactone 25 mg. Include a "Medications to AVOID in elderly" box: atenolol, alpha-blockers as monotherapy, clonidine, short-acting nifedipine, combined ACE-I + ARB. Show target BP ranges stratified by patient type: robust (SBP <130), typical elderly (SBP 130-139), frail (SBP <150), advanced dementia/EOL (individualize, often SBP <150-160). Include monitoring requirements: electrolytes at 2-4 weeks, orthostatic BP at every visit, renal function with RAAS inhibitors.</image>

Key Clinical Pearls

• Always check orthostatic blood pressure in elderly patients — 20-30% have concurrent supine hypertension and orthostatic hypotension; treating one may worsen the other
• SPRINT showed benefit of intensive treatment even in ≥75, but used AOBP — a SPRINT target of <120 corresponds to approximately <130 with conventional office measurement
• Chlorthalidone is preferred over HCTZ for hypertension treatment — more evidence, longer duration, more potent; but monitor closely for hyponatremia (especially in thin elderly women)
• Beta-blockers are NOT first-line for uncomplicated hypertension in elderly — they are inferior for stroke prevention (LIFE trial); reserve for HF, post-MI, or AF
• In advanced dementia, aggressive BP lowering (SBP <130 on ≥2 agents) may INCREASE cognitive decline and mortality (PARTAGE) — liberalize targets to SBP 140-160 when goals are comfort-focused
• Most elderly patients need ≥2 antihypertensives — single-pill combinations improve adherence and should be used whenever possible
• Spironolactone 25 mg is the most effective add-on for resistant hypertension regardless of age (PATHWAY-2)

References

1. SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103-2116.
2. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older (HYVET). N Engl J Med. 2008;358(18):1887-1898.
3. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):e13-e115.
4. Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874-2071.
5. Benetos A, Labat C, Rossignol P, et al. Treatment with multiple blood pressure medications, achieved blood pressure, and mortality in older nursing home residents: the PARTAGE study. JAMA Intern Med. 2015;175(6):989-995.

Read this lecture as Markdown